Akoya Biosciences, Inc. provided revenue guidance for the year 2022. The Company, based on its updated plans and initiatives, is raising its full year 2022 revenue guidance range to $73 million to $75 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.16 USD | +9.92% | -15.91% | -54.51% |
05-15 | Piper Sandler Cuts Akoya Biosciences Price Target to $6 From $8, Maintains Overweight Rating | MT |
05-14 | Top Midday Decliners | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-54.51% | 97.04M | |
+8.13% | 223B | |
+13.57% | 195B | |
+19.08% | 144B | |
+30.01% | 111B | |
+2.93% | 65.19B | |
+15.04% | 53.02B | |
+3.64% | 50.28B | |
+8.23% | 44.15B | |
+2.75% | 36.45B |
- Stock Market
- Equities
- AKYA Stock
- News Akoya Biosciences, Inc.
- Akoya Biosciences, Inc. Provides Revenue Guidance for the Year 2022